psg esports
Opening a window is not just about letting the outside world in; it is also about allowing ourselves to connect with nature and take a moment to breathe. The sensation of a gentle breeze on our face, the sounds of birds chirping in the distance, and the sight of sunlight streaming through the glass can all work wonders for our well-being.
NORTON -- Virginia Gov. Glenn Youngkin on Friday announced the relocation of Wrap Technologies to Southwest Virginia, marking a significant expansion of the company’s commitment to defense and public safety technology. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.In conclusion, the “thread the needle” accident between the small car and the truck underscored the complexities of human behavior and the inherent uncertainties of navigating through modern traffic. While blame and fault may linger in the aftermath of such incidents, it is essential for all road users to strive for greater awareness, responsibility, and compassion in order to prevent future accidents and ensure the safety of all.Overall, the Honor GT promises to be a game-changer in the mobile gaming landscape, combining cutting-edge technology, innovative features, and the expertise of KPL Champion Yino to deliver an unparalleled gaming experience. Stay tuned for more updates on the Honor GT as we approach the official launch date on December 16th.
Two men have been arrested after around £20,000 of stock was stolen from a phone shop. Staff at the Vodafone shop on Marlborough High Street told Wiltshire Police they were threatened before the men left. The men fled and were briefly pursued by officers on the A338 before they were arrested on suspicion of robbery near Hungerford. Both are in custody, with police asking anyone with dashcam footage of the incident at around 16:00 GMT on Saturday to come forward. The driver of the car was also arrested on suspicion of dangerous driving.
Title: Atomic Heart New DLC "Deep Sea Enchantment" Teaser: Set to Launch on 1.28 Next YearNigerian music consumption soars 146% in 2024 – Spotify
"Sonic the Hedgehog 3" promises to deliver an action-packed experience that will keep players on the edge of their seats. With updated graphics, new challenges, and familiar faces, this installment is sure to be a hit among both longtime fans and newcomers to the Sonic franchise.
President Javier Milei has said that the Senate session in which Edgardo Kueider was expelled over corruption allegations was void because his vice, Victoria Villarruel, led the session while acting as president of the nation. Milei traveled to Italy on Thursday, leaving Villarruel as acting president, but she has responded publicly that she was not formally transferred the presidential power until after the session had ended. The episode underscores the increasingly public rift between the president and his second-in-command. “The session is invalid,” Milei said on Friday during an interview with Luis Majul on radio station El Observador. On Thursday, the Upper House voted to expel Senator Edgardo Kueider from Congress after he was arrested in Paraguay with over US$200,000 of undeclared cash while crossing the border from Brazil. Kueider was a Peronist lawmaker, but voted for Milei’s flagship bill, the Ley Bases. Like Milei, his lawyer said the session was null and filed a writ for Kueider to be reinstated. In Argentina, the Vice President is also head of the senate. However, Milei argued that Villarruel should not have presided over the session because he was in Rome and she should have been the acting president, not the head of the Senate. Milei said that, according to current legislation, the vice president “automatically” acts as president if the president travels overseas. That role is then occupied by the provisional spokesperson of the Senate, who is currently Bartolomé Abdala. “If she presides over the session of the Congress, she is working in the Legislative Branch, but at the same time, she is the acting president of the nation [...,] she is occupying two positions, and that violates the separation of powers,” he said. Villarruel responded that the temporary transfer of power did not take effect until it had been formally signed off. “Until the power of attorney [to be President] is transferred to me, I am vice president. And that is done through the presidency’s notary. I signed the minutes giving my consent at 7:00 p.m.,” Villarruel wrote, answering a comment on her Instagram account. Screenshots of what appears to be a chat with Villarruel’s secretary were published by various news websites. They show a conversation timestamped 8:36 a.m. on Tuesday, stating the president’s time of departure and arrival. The secretary responds “OK” to the messages. The chats also show a letter notifying Villarruel of Milei’s trip through the Electronic Document Management System (GDE, by its Spanish acronym), which stores all proceedings and files within the public administration. Milei mentioned the letter in his interview. A spokesperson for Villarruel told the Herald that Villarruel was not aware of the trip, that the Legislative Branch does not use the GDE, and that the vice president does not have a username for the system in the Senate building. Milei’s trip to Italy, although not his departure time, had been reported by media including the Herald over a week before he departed. The relationship between Milei and Villarruel has been strained for months, with the president calling her part of the “caste” and leaving her off the guestlist for government events. She was not present for Milei’s first anniversary speech celebrating one year in power. “I would have loved to be there,” Villarruel wrote in a comment on her Instagram account. Villarruel lamented that Kueider was expelled from the Congress, implying that she does not consider him a member of the Peronist bloc. Since Kueider entered Congress on a Peronist ticket, his seat will now be granted to Stefania Cora, who is associated with Maximo Kirchner’s organization La Cámpora. “We are going to work until our last breath so that the [Kirchners] no longer manage the designs of our country,” Villarruel wrote on X. Meanwhile, Kueider is currently being investigated in Paraguay for attempted smuggling. Peronist senator Oscar Parrilli, social democrat deputy Margarita Stolbizer, and left-wing former deputy Myriam Bregman have suggested that Kueider was smuggling money from a government bribe to vote for the Ley Bases. Investigators have not reached any formal conclusions about the origin of the funds. Bregman’s party, the Party of the Socialist Workers (PTS) demanded that the Ley Bases be declared void. The vote on the controversial bill was tied in Argentina’s senate, with Villarruel casting the deciding vote in favor of the government.In navigating the challenges of the antitrust investigation, NVIDIA is guided by the conviction that it will prevail through the strength of its products, the integrity of its practices, and the dedication of its team. The company acknowledges the importance of regulatory scrutiny in ensuring a level playing field and promoting healthy competition. By engaging constructively with regulators and stakeholders, NVIDIA aims to address any concerns transparently and proactively, laying the foundation for a sustainable and ethical business environment.
In the end, regardless of the outcome of the match, one thing is certain: Krunic's return to San Siro is a testament to his talent, his dedication, and his unwavering love for the sport. As the fans cheer him on and the spotlight shines brightly upon him, Krunic will once again write his name in the annals of AC Milan's history, reinforcing his legacy as a player who gave his all for the red and black.Netflix continues to express confidence that its streaming platform is prepared to handle the massive audiences expected for a pair of Christmas Day NFL games along with the start of its live coverage of the World Wrestling Entertainment's "Raw" next month. Concerns were raised after users experienced issues with buffering and low quality feeds during the Jake Paul-Mike Tyson boxing match last month. Netflix has exclusive rights to stream NFL games on Christmas Day between the Kansas City Chiefs at the Pittsburgh Steelers and the Baltimore Ravens at the Houston Texans. Beyonce is scheduled to perform during halftime of the Ravens-Texans game, which could create more server traffic Netflix must take into account. It's a major test after the company reported an average global live audience of 108 million viewers for Paul's victory over Tyson in Arlington, Texas. Downdetector.com , which tracks service outages, announced that there were 90,000 issues reported at one point. "It was a big number, but you don't know, and you can't learn these things until you do them, so you take a big swing," Netflix chief content officer Bela Bajaria told Front Office Sports. "Our teams and our engineers are amazing, moved super quickly, and stabilized it, and many of the members had it back up and running pretty quickly. But we learn from these things. "We've all obviously done a lot of stuff to learn and get ready for the NFL and Beyonce, and so we're totally ready and excited for WWE." WWE president Nick Khan told FOS that Raw's tone and content will not change as it moves to the streaming service, with its first event of 2025 scheduled for Jan. 6. "There's some online chatter about, ‘oh, it's going to be R-rated, or for us old folks, X-rated.' That's definitely not happening," Khan said. "It's family-friendly, multi-generational, advertiser-friendly programming. It's going to stay that way. I would look for more global flair, especially as the relationship continues to develop." --Field Level Media
Top ranked chess player Magnus Carlsen has left the World Rapid and Blitz Chess Championships after refusing to change out of the jeans he wore to the competition, the International Chess Federation said. The federation said in a Friday statement that its regulations include a dress code that bars participants from wearing jeans at the event. "The Chief Arbiter informed Mr Carlsen of the breach, issued a $US200 ($A322) fine, and requested that he change his attire," the federation said in the statement posted to its website. "Unfortunately, Mr Carlsen declined, and as a result, he was not paired for round nine. This decision was made impartially and applies equally to all players." The 34-year-old Norwegian chess grandmaster said in a video from his Take Take Take chess app that he posted on the social platform X that he accepted the fine. But he refused to change his pants before quitting the competition in New York. "I said, 'I'll change tomorrow if that's OK," Carlsen said in the video. "But they said, 'Well, you have to change now.' At that point it became a bit of a matter of principle for me." The federation said in its statement that the dress code is "designed to ensure professionalism and fairness for all participants." It said fellow participant Ian Nepomniachtchi was also fined earlier Friday for breaching the dress code by wearing sports shoes. "However, Mr Nepomniachtchi complied, changed into approved attire, and continued to play in the tournament," the statement said. "These rules have been in place for years and are well-known to all participants and are communicated to them ahead of each event."In conclusion, the abandonment of over 50 elderly people after a 9.9 RMB day trip is a sobering reminder of the need for compassion, accountability, and vigilance in the tourism industry. May this tragic event serve as a catalyst for positive change and a renewed commitment to the safety and well-being of all travelers, regardless of age or background.Photo: Kylie Kelce Instagram Pregnancy is often portrayed as a magical journey, but Kylie Kelce , wife of Philadelphia Eagles legend Jason Kelce , isn’t holding back about the challenges of carrying a child.The couple recently announced they’re expecting their fourth daughter, and Kylie has opened up about the realities of pregnancy in her debut podcast episode of " Not Gonna Lie with Kylie Kelce ." Also read - Taylor Swift and Travis Kelce to Celebrate Christmas Together – Here’s What We Know! Staying True to Pregnancy While thanking God for the chance to conceive, Kylie candidly admitted, "I always say I am so incredibly grateful to be able to get pregnant. Unbelievably grateful. I have realized in my adult life that it is not as easy to get pregnant as we originally let on to believe in high school. You can't just look at someone and whoop there you go. It's not that easy." For her, the destination is more important than the journey. Kylie shared ongoing battles with morning sickness and nausea and how society expects to see pregnancy as a beautiful time. Her honesty feels like a breath of fresh air in a world where such topics are often sugar-coated. "I'm nauseous for most of my pregnancy," she said, adding that even past the first trimester, the sickness lingers. And don't get her started on the well-meaning compliments. "When someone says, 'Isn't this the most beautiful thing ever?' I want to punch them in the face, " Kylie joked. Kylie on Pregnancy Reaction, Parenting with Jason & Raising Boys vs Girls with Kaitlin Olson | Ep. 1 This is a new chapter in her life as she shares the motherhood journey in her own words. She is looking forward to normalizing the complexities of pregnancy and giving room for honest discussions on parenthood. Fans have appreciated her refreshing approach, since rarely would someone in the limelight share such raw experiences. A Playful Pregnancy Announcement The Kelce family announced their growing brood on Instagram in November with an adorable photo of their three daughters donning "Big Sister" sweaters. Each of the girls—Wyatt, Elliotte, and Bennett—displayed hilariously different reactions, perfectly capturing the excitement, fear, and joy of welcoming a new sibling. Jason Kelce even chimed in on the excitement during his "New Heights" podcast, sharing how thrilled he is to welcome another baby girl. Celebrating Parenthood Kylie and Jason's journey throws out all the highs and lows of creating a family. Their house is about to get much more lively because of this new baby that's on the way. Whether through her podcast or their playful social media updates, Kylie continues to redefine what it means to be a modern mom, one honest conversation at a time. Also read - What Taylor Swift’s Spotify Wrapped Win Means for the NFL and Travis Kelce
As the years went by, Nani's career at Manchester United flourished. He played alongside footballing legends, won numerous titles, and etched his name into the club's history. Despite facing challenges and setbacks along the way, he never wavered in his dedication and passion for the game.In conclusion, the Premier League dribble success leaders of the season showcase the skill and determination of the top players in English football. Zaha's 3.8 successful dribbles per game and Richarlison's 3.2 successful dribbles per game are a testament to their individual quality and the impact they have on their teams. As fans, we can only sit back and enjoy the artistry and excitement of these players as they continue to light up the Premier League with their dribbling prowess.
In the world of celebrity couples, every detail matters – including their hairstyles. And when it comes to power couple Xiao Hua and Xiang Zuo, the stakes are even higher. Recently, the final hairstyle that Xiao Hua crafted for Xiang Zuo was revealed in a live broadcast, attracting a staggering 67 million viewers.
Netflix 'totally ready' for XMas NFL games, WWESAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.
In addition to expanding its presence in Nanjing, Amazon is committed to supporting local communities and promoting sustainable practices. The company plans to engage in various CSR initiatives, such as environmental conservation and community outreach programs, to make a positive impact on society.
In conclusion, while the specifics of Xbox's plans remain shrouded in mystery, the hints dropped by the renowned journalist have sparked a frenzy of excitement among fans. Whether it be new exclusive titles, exciting partnerships, or a long-term roadmap for the future, one thing is certain – Xbox is poised to make a splash at TGA and beyond. Stay tuned for more updates as the gaming world eagerly awaits the big reveals from Xbox.
Rescuers reassess safety in search for woman they think fell into a Pennsylvania sinkhole
By DAVID BAUDER Time magazine gave Donald Trump something it has never done for a Person of the Year designee: a lengthy fact-check of claims he made in an accompanying interview. Related Articles National Politics | Trump’s lawyers rebuff DA’s idea for upholding his hush money conviction, calling it ‘absurd’ National Politics | Ruling by a conservative Supreme Court could help blue states resist Trump policies National Politics | A nonprofit leader, a social worker: Here are the stories of the people on Biden’s clemency list National Politics | Nancy Pelosi hospitalized after she ‘sustained an injury’ on official trip to Luxembourg National Politics | Veteran Daniel Penny, acquitted in NYC subway chokehold, will join Trump’s suite at football game The fact-check accompanies a transcript of what the president-elect told the newsmagazine’s journalists. Described as a “12 minute read,” it calls into question 15 separate statements that Trump made. It was the second time Trump earned the Time accolade; he also won in 2016, the first year he was elected president. Time editors said it wasn’t a particularly hard choice over other finalists Kamala Harris, Elon Musk, Benjamin Netanyahu and Kate Middleton. Time said Friday that no other Person of the Year has been fact-checked in the near-century that the magazine has annually written about the figure that has had the greatest impact on the news. But it has done the same for past interviews with the likes of Joe Biden, Netanyahu and Trump. Such corrections have been a sticking point for Trump and his team in the past, most notably when ABC News did it during his only debate with Democrat Kamala Harris this fall. There was no immediate response to a request for comment on Friday. In the piece, Time called into question statements Trump made about border security, autism and the size of a crowd at one of his rallies. When the president-elect talked about the “massive” mandate he had received from voters, Time pointed out that former President Barack Obama won more electoral votes the two times he had run for president. The magazine also questioned Trump’s claim that he would do interviews with anyone who asked during the campaign, if he had the time. The candidate rejected a request to speak to CBS’ “60 Minutes,” the magazine said. “In the final months of his campaign, Trump prioritized interviews with podcasts over mainstream media,” reporters Simmone Shah and Leslie Dickstein wrote. David Bauder writes about media for the AP. Follow him at http://x.com/dbauder and https://bsky.app/profile/dbauder.bsky.social.In contrast, thirteenth month pay is typically a fixed amount that is equal to one month's salary. This standardized calculation method ensures that all employees receive the same bonus amount, regardless of their performance or position within the company. Thirteenth month pay is seen as a form of social benefit that aims to provide financial stability and support to employees, especially those in lower-wage brackets.